financetom
Market
financetom
/
Market
/
March FMCG sales fall; down-trading witnessed across categories
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
March FMCG sales fall; down-trading witnessed across categories
Apr 4, 2022 5:27 AM

The impact of inflation and price hikes is being seen on-ground in FMCG sales at kirana stores. Data from Bizom shows FMCG sales fell over 5 percent in March compared to February. The report further states that monthly sales per kirana stores also fell over 10 percent.

Share Market Live

NSE

Bizom says that sustained high inflation could create pressure on consumer usage and further lower volumes in the coming months.

Looking at FMCG sales category wise, sales of essential commodities like pulses, oils, etc. fell by over 32 percent in March compared to Feb and over 11 percent compared to March last year.

Similarly, personal care, confectionery and homecare also saw a decline in sales. The only outlier was beverage sales, which thanks to an early summer and restrictions being lifted, rose a whopping 172 percent.

Also Read: FMCG makers to go for 10% price hike to mitigate inflationary pressures

The fall in sales in other categories, Bizom says is because consumers are actively down trading to smaller packs as prices pinch their wallets. Data shows that in both rural and urban India, the sales contribution from lower-priced packs in commodities, beverages, home care products and packaged foods have seen an increase of anywhere between 5-9 percent, while that of higher-priced packs fell by anywhere between 2-14 percent.

Also Read: FMCG companies should increase margins for kirana stores: METRO Cash & Carry India MD

Consumers are cutting down consumption as prices continue to surge and companies like HUL have alluded to this as well.

(Edited by : Abhishek Jha)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FedEx climbs on cheery annual profit forecast, freight business review
FedEx climbs on cheery annual profit forecast, freight business review
Jun 26, 2024
(Reuters) -FedEx ( FDX ) shares jumped 13% premarket on Wednesday after the delivery giant reassured investors with a largely upbeat annual profit forecast and said it would weigh options for its less-than-truckload business that one analyst valued at $30 billion. On Tuesday, the company projected fiscal 2025 earnings of $20 to $22 per share - the midpoint of which...
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
NeuroBo Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
Jun 26, 2024
The Dow Jones index closed lower by around 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny...
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday As Traders Await Fresh Catalysts
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Wednesday As Traders Await Fresh Catalysts
Jun 26, 2024
08:25 AM EDT, 06/26/2024 (MT Newswires) -- The broad market exchange-traded fund SPDR S&P 500 ETF Trust ( SPY ) was marginally lower and the actively traded Invesco QQQ Trust (QQQ) was 0.1% higher in Wednesday's premarket activity, as traders waited for fresh catalysts and clues about the US Federal Reserve's interest rate policy. US stock futures were also mixed,...
Sector Update: Health Care
Sector Update: Health Care
Jun 26, 2024
08:56 AM EDT, 06/26/2024 (MT Newswires) -- Health care stocks were flat to lower pre-bell Wednesday with the iShares Biotechnology ETF (IBB) inactive and the Health Care Select Sector SPDR Fund (XLV) down 0.01% recently. Savara (SVRA) rose nearly 21% after saying the phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of Molgramostim in adult patients with autoimmune...
Copyright 2023-2025 - www.financetom.com All Rights Reserved